Evidence map›Paper›PMID 30271076›Full record

ArticleWorld journal of gastroenterology2018

Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.

Ioanna Aggeletopoulou, Stelios F Assimakopoulos, Christos Konstantakis, Christos Triantos

Open access · hybridAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ioanna AggeletopoulouDivision of Gastroenterology, Department of Internal Medicine, Medical School, University of Patras, Patras 26504, Greece.
Stelios F AssimakopoulosDepartment of Internal Medicine, University Hospital of Patras, Patras 26504, Greece.
Christos KonstantakisDivision of Gastroenterology, Department of Internal Medicine, Medical School, University of Patras, Patras 26504, Greece.
Christos TriantosDivision of Gastroenterology, Department of Internal Medicine, Medical School, University of Patras, Patras 26504, Greece. chtriantos@upatras.gr.
University of Patras · GRGeneral University Hospital of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Considering that both innate and adaptive immune responses are involved in the pathogenesis of Crohn's disease (CD), novel therapeutic options have significantly been developed. Biological agents represent an important addition to the conventional treatments for immuno-inflammatory conditions, acting as antagonists of adhesion molecules or various inflammatory cytokines. The interleukin 12 (IL-12)/IL-23 common pathway has been found to play a determinant role in the induction of inflammation in adaptive immune responses. In particular, IL-23 promotes the differentiation of naïve T helper cells into Th17 phenotype with the concomitant secretion of several inflammatory cytokines such as IL-17 and IL-22, whereas IL-12 induces the Th1 polarization and production of critical cytokines such as interferon-γ and tumor necrosis factor. Nowadays, there is increased interest regarding the role of IL-23 as a therapeutic target of CD through the blockage of IL-23 mediated pathways. In this editorial, we focus on the role of IL-12/IL-23 pathway in the regulation of mucosal immunity and in the induction and maintenance of chronic inflammation. In parallel, we critically discuss the available data regarding the therapeutic effect of the IL-12/IL-23 inhibitors and especially of ustekinumab, a human monoclonal antibody which has been recently approved by the United States Food and Drug Administration for the management of moderate-to-severe CD and its potential to be used as first-line therapy in everyday clinical practice.

Indexed as

Cell DifferentiationCrohn DiseaseGastrointestinal AgentsHumansImmunity, MucosalInterleukin-12Interleukin-23Signal TransductionT-Lymphocytes, Helper-InducerTreatment OutcomeUstekinumabGastrointestinal AgentsInterleukin-12Interleukin-23UstekinumabBiological agentsCrohn’s diseaseInterleukin 12Interleukin 12/interleukin 23 blockadeInterleukin 23Monoclonal antibodiesUstekinumab

Identifiers

PMID30271076
PMCPMC6158482
OpenAlexW2893094758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.